

Journal Pre-proof

[[Translated article]]Analyzing the quality of life of individuals with cutaneous lymphomas

A. Sánchez-Merino F. Vílchez-Márquez A. Ruíz-García C.
Botella-García S. Arias-Santiago



PII: S0001-7310(25)00509-5

DOI: <https://doi.org/doi:10.1016/j.ad.2025.07.014>

Reference: AD 4453

To appear in: *Actas dermosifiliograficas*

Received Date: 23 June 2024

Accepted Date: 25 August 2024

Please cite this article as: Sánchez-Merino A, Vílchez-Márquez F, Ruíz-García A, Botella-García C, Arias-Santiago S, [[Translated article]]Analyzing the quality of life of individuals with cutaneous lymphomas, *Actas dermosifiliograficas* (2025), doi: <https://doi.org/10.1016/j.ad.2025.07.014>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2025 AEDV. Published by Elsevier España, S.L.U.

Refers to AD_4372

Comunicación Breve

Análisis de la calidad de vida en los pacientes con linfomas cutáneos

[[Translated article]]Analyzing the quality of life of individuals with cutaneous lymphomas

A. Sánchez-Merino^a, F. Vílchez-Márquez^{b,c,*}, A. Ruíz-García^d, C. Botella-García^d, S. Arias-Santiago^{b,c,e}

^a Facultad de Medicina, Universidad de Granada. Granada, España.

^b Servicio de Dermatología, Hospital Universitario Virgen de las Nieves, Granada, España.

^c Instituto de investigación biosanitaria ibs.GRANADA. Granada, España.


^d Servicio de Hematología. Hospital Universitario Virgen de las Nieves, Granada, España.

^e Departamento de Dermatología, Facultad de Medicina, Universidad de Granada. Granada, España.

* Autor para correspondencia:

E-mail: fvilchezm@hotmail.com.

Graphical abstract



Abstract. Primary cutaneous lymphomas are a heterogeneous group of non-Hodgkin's lymphomas, most of them chronic with multiple relapses, which can have an impact on the patient's quality of life. The main aim of the study was to assess the quality of life of patients with cutaneous lymphomas using different validated questionnaires. A total of 32 patients were included in the study (mean age, 64 years; 75% men). A total of 68.8% of lymphomas were mycosis fungoides. Age, number of therapies administered and pruritus were associated with worse quality of life as assessed by the different questionnaires. The use of quality of life-questionnaires may be useful in the holistic evaluation of the patient.

Keywords: primary cutaneous lymphomas; quality of life; quality of life questionnaires; health-related quality of life.

Resumen. Los linfomas cutáneos primarios son un grupo heterogéneo de linfomas de tipo no Hodgkin, la mayoría de carácter crónico con múltiples recaídas, que pueden provocar una repercusión en la calidad de vida. El objetivo principal del estudio fue evaluar la calidad de vida de pacientes con linfomas cutáneos mediante el empleo de diferentes cuestionarios validados. Se incluyeron 32 pacientes en el estudio, con una edad media de 64 años, siendo el 75% hombres y el 68,8% de los linfomas de tipo micosis fungoide. La edad, el número de tratamientos empleados y el prurito se asociaron a una peor calidad de vida, evaluada por los diferentes cuestionarios. El empleo de cuestionarios de calidad de vida puede ser útil en la evaluación holística del paciente.

Palabras clave: linfomas cutáneos primarios; calidad de vida; cuestionarios de calidad de vida; calidad de vida relacionada con la salud.

Introduction

Primary cutaneous lymphomas (PCLs) represent a heterogeneous group of non-Hodgkin lymphomas whose first clinical manifestation occurs in the skin without evidence of extracutaneous involvement at the time of diagnosis¹. A total of 75% to 80% of PCLs are cutaneous T-cell lymphomas (CTCLs), and the remaining 20-25%, cutaneous B-cell lymphomas (CBCLs)². Of all these, mycosis fungoides (MF) is the most frequent form, which, along with Sézary syndrome (SS), accounts for almost half of all PCLs³.

Currently, there is no curative treatment, so most PCLs run a chronic course with multiple relapses. Furthermore, the visibility of the lesions along with skin involvement such as itching, desquamation, and pain can significantly impact the patients' quality of life (QOL)^{4,5}. In PCLs, the use of questionnaires to assess QOL has been poorly studied, with existing studies focusing on CTCLs⁶⁻¹². Therefore, we initiated this study with the primary endpoint of evaluating QOL in patients with PCLs. Secondly, we aimed to explore factors associated with poorer QOL and compare QOL between patients with MF, as it is the most frequent type, and other PCLs.

Patients and Methods

We conducted a cross-sectional study with patients diagnosed with any type of PCL, regardless of their severity and treatment level on therapy at the Cutaneous Lymphoma Unit of Hospital *Universitario Virgen de las Nieves*. The patient inclusion period for the study went from February to May 2024.

Demographic and clinical data (age, sex, type of lymphoma, duration of evolution, etc.) were collected, and the various study questionnaires were completed. Questionnaires related to disease severity were the Modified Severity-Weighted Assessment Tool (mSWAT) and the Itch Severity Scale (ISS). Questionnaires to evaluate quality of life and well-being were Skindex-29, the Dermatology Life Quality Index (DLQI), the Hospital Anxiety and Depression Scale (HADS), and the WHO-5 Well-Being Index questionnaire.

All statistical analyses were performed with the SPSS® package (SPSS for Mac, Version 21.0 Chicago: SPSS Inc.).

Results

A total of 32 patients with PCLs were included in the study, with a mean course of the disease of 79.31 ± 79.02 months. The clinical/epidemiological characteristics studied are shown in Table 1.

Bivariate analysis was performed to identify factors associated with a poorer quality of life (Table 2). Older age was associated with a higher DLQI score ($p = 0.039$). A higher Skindex-29 score was found in patients with a greater number of previous treatments ($p = 0.035$). Finally, the presence of pruritus was statistically significantly associated with higher scores on Skindex-29 ($p < 0.001$), DLQI ($p < 0.001$), WHO-5 ($p = 0.003$), and HADS, in both the anxiety ($p = 0.007$) and the depression subscales ($p = 0.010$). No statistically significant findings were found for the rest of the variables.

Bivariate analysis was performed to compare quality of life between patients with MF, as it is the most frequent type, and other PCLs. The prevalence of pruritus in patients with mycosis fungoides was 75%, while in the group of other cutaneous lymphomas it was 41.7%; of the total patients with pruritus, only 1 had B-cell lymphoma, being the remaining 19 T-cell lymphomas. Nonetheless, no statistically significant differences were found. No statistically significant differences were found either between MF and other PCLs in the different quality of life questionnaires used.

Finally, the relationship between Skindex-29 and ISS scores was analyzed using linear regression (Fig. 1). It was observed that for every increase in the ISS score, Skindex-29 increased by 1.14 points ($p < 0.001$; $R = 0.721$).

Discussion

In this study, several factors associated with a poorer quality of life in patients with PCLs were found, such as age, the number of previous treatments received, or the presence of pruritus. The variety of questionnaires used in the literature to assess QOL in PCL patients complicates the comparison of obtained data, in addition to the fact that

most studies focus on QOL in CTCL patients⁶⁻¹⁴, with very few including all types of PCLs^{5, 15, 16}. Despite this, we observed that older patients had a higher DLQI score, and thus a greater impact on their QOL, which is consistent with former studies^{5, 6, 16}. Other factors classically associated with poorer QOL in PCL patients such as female sex, Black patients, advanced disease stages, SS, psychiatric comorbidity, or type of treatment^{4, 7} were not found in our study, probably due to the inclusion of all PCL types (not just MF/SS); the small sample size; and the absence of patients with SS or from different ethnic/racial groups.

On the other hand, the study found more cases of severe Skindex-29 in patients with > 2 previous treatments. It has been reported that treatment with corticosteroids or interferon is associated with a poorer QOL⁵, mainly due to its association with anxiety and depression. However, the association between the number of previous treatments and severe cases in Skindex-29 has not been described in the literature to this date. This association can be interpreted as patients who have been treated with > 2 treatments having a worse QOL, since for them the use of different therapeutic measures has not been effective, and therefore their impairment is greater as clinical control of the disease has not been achieved. This is, therefore, an important piece of data to consider in the clinical and therapeutic management of these patients.

Although our study found no association between QOL and HADS, the results show that probably up to 5 patients could have been diagnosed with anxiety, and up to 2 with depression. This fact is of great importance, as numerous studies emphasize the impact on PCL patients not only physically, but also emotionally, economically, and functionally, which negatively influences their QOL⁹⁻¹¹. A recently published study shows the cost of treatment and care for PCL patients in Spain¹⁷, reflecting the economic component of the disease, especially in countries where patients bear the costs.

The main finding of our study is that the presence of pruritus is associated with higher scores on Skindex-29, DLQI, WHO-5, and HADS, in both the anxiety and depression subscales. Furthermore, a positive association was observed between ISS and Skindex-29 values. Pruritus was therefore the most debilitating symptom and the one most associated with a decrease in QOL as measured by the different questionnaires in the study, which is consistent with current studies^{4, 5, 18}, where pruritus is described by patients as the most frequent symptom and the one that most affected their daily lives, interfering with sleep and being associated with a great impact on QOL. This symptom is common in PCLs, but it is more frequent in CTCLs, where worsening pruritus is associated with disease progression, relapse, or infection, making its therapeutic management especially important to improve patients' QOL¹⁹. In accordance with published literature, in our study, pruritus affected CTCL patients more, with only 1 patient with CBCL complaining of this symptom, so in this group, the impact on their QOL could be due to different causes.

Finally, no differences in QOL were found between MF and other PCLs across the different questionnaires used. We believe this is due to the underrepresentation of non-MF PCLs in the sample. Some studies suggest that CTCLs have worse QOL vs CBCLs¹⁵; even so, this is an understudied area where more research is needed to clarify this issue.

The main limitations of the study were its cross-sectional design, which means that causal associations cannot be established due to lack of follow-up; the small sample size, with a small proportion of non-MF PCLs; and the lack of a control group.

In conclusion, our study demonstrates that patients with PCLs experience an impact on their QOL, with pruritus being the most limiting factor in this regard. Since all that has been stated previously, and considering the chronic nature of this disease, along with the lack of a curative treatment, and the impact on QOL suffered by patients, the development of a specific questionnaire for PCLs remains of paramount importance.

Ethical Considerations

This study was approved by the Provincial Ethics Committee for Research of Granada, in full compliance with the Declaration of Helsinki. Informed consent was obtained from participants, either verbally or in writing. The confidentiality of participant data was rigorously preserved, with an anonymous database used for analysis.

Funding

None declared.

Conflicts of interest

None declared.

References

<BIBL>

<BIB>

1

BST WHO Classification of Tumours Editorial Board. Haematolymphoid tumours [Internet; beta version ahead of print]. WHO classification of tumours series

EDN 5th ed.

V 11

PL Lyon, France

PN International Agency for Research on Cancer

D 2022

<original_ref>[1] <BT>WHO Classification of Tumours Editorial Board.

Haematolymphoid tumours [Internet; beta version ahead of print]. WHO classification of tumours series</BT>, <EDN>5th ed.</EDN>, 11 Lyon, France: International Agency for Research on Cancer; 2022.</original_ref>

</BIB>

<BIB>

2

S Willemze F R.

S Cerroni F L.

S Kempf F W.

S Berti F E.

S Facchetti F F.

S Swerdlow F S.H.<ET-AL>

AT The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas

JT Blood

V 133

D 2019

P 1703-L 1714

<original_ref>[2] Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133<I>(16)</I>:1703-14.</original_ref>

</BIB>

<BIB>

3

S Dummer F R.

S Vermeer F M.H.

S Scarisbrick F J.J.

S Kim F Y.H.

S Stonesifer F C.

S Tensen F C.P.<ET-AL>

AT Cutaneous T cell lymphoma

JT Nat Rev Dis Primer

V 7

D 2021

P 61

<original_ref>[3] Dummer R, Vermeer MH, Scarisbrick JJ, Kim YH, Stonesifer C, Tensen CP, et al. Cutaneous T cell lymphoma. Nat Rev Dis Primer.

2021;7<I>(1)</I>:61.</original_ref>

</BIB>

<BIB>

4

S Jonak F C.

S Porkert F S.

S Oerlemans F S.

S Papadavid F E.

S Molloy F K.

S Lehner-Baumgartner F E.<ET-AL>

AT Health-related Quality of Life in Cutaneous Lymphomas: Past, Present and Future

JT Acta Derm Venereol

V 99

D 2019

P 640-L 646

<original_ref>[4] Jonak C, Porkert S, Oerlemans S, Papadavid E, Molloy K, Lehner-Baumgartner E, et al. Health-related Quality of Life in Cutaneous Lymphomas: Past, Present and Future. Acta Derm Venereol. 2019;99<I>(7)</I>:640-6.</original_ref>

</BIB>

<BIB>

5

S Sampogna F F.

S Frontani F M.

S Baliva F G.

S Lombardo F G.A.

S Alvetreti F G.

S Di Pietro F C.<ET-AL>

AT Quality of life and psychological distress in patients with cutaneous lymphoma

JT Br J Dermatol

V 160

D 2009

P 815-L 822

<original_ref>[5] Sampogna F, Frontani M, Baliva G, Lombardo GA, Alvetreti G, Di Pietro C, et al. Quality of life and psychological distress in patients with cutaneous lymphoma. Br J Dermatol. 2009;160<I>(4)</I>:815-22.</original_ref>

</BIB>

<BIB>

6

S Demierre F M.F.

S Gan F S.

S Jones F J.

S Miller F D.R.

AT Significant impact of cutaneous T-cell lymphoma on patients' quality of life: Results of a 2005 National Cutaneous Lymphoma Foundation Survey

JT Cancer

V 107

D 2006

P 2504-L 2511

<original_ref>[6] Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer. 2006;107<I>(10)</I>:2504-11.</original_ref>

</BIB>

<BIB>

7

S Shinohara F M.M.

S Mahurin F H.M.

S Tarabdkar F E.

S Hippe F D.S.

S Lachance F K.

S Kim F E.J.<ET-AL>

AT Health-related quality of life in cutaneous T-cell lymphoma: A cross-sectional survey study

JT Skin Health Dis

V 1

D 2021

P e45

<original_ref>[7] Shinohara MM, Mahurin HM, Tarabdkar E, Hippe DS, Lachance K, Kim EJ, et al. Health-related quality of life in cutaneous T-cell lymphoma: A cross-sectional survey study. Skin Health Dis. 2021;1<I>(3)</I>:e45.</original_ref>

</BIB>

<BIB>

8

S Rosenthal F J.M.

S Kim F E.J.

AT Health-related quality of life in cutaneous T-cell lymphoma: Examining all sides of the issue

JT Br J Dermatol

V 182

D 2020

P 20-L 21

<original_ref>[8] Rosenthal JM, Kim EJ. Health-related quality of life in cutaneous T-cell lymphoma: examining all sides of the issue. Br J Dermatol.

2020;182<I>(1)</I>:20-1.</original_ref>

</BIB>

<BIB>

9

S Dalal F M.

S Mitchell F S.

S McCloskey F C.

S Zagadailov F E.

S Gautam F A.

AT The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: Results of a systematic review

JT Expert Rev Hematol

V 13

D 2020

P 405-L 419

<original_ref>[9] Dalal M, Mitchell S, McCloskey C, Zagadailov E, Gautam A. The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review. Expert Rev Hematol.

2020;13<I>(4)</I>:405-19.</original_ref>

</BIB>

<BIB>

10

S Holahan F H.M.

S Farah F R.S.

S Fitz F S.

S Mott F S.L.

S Ferguson F N.N.

S McKillip F J.<ET-AL>

AT Health-related quality of life in patients with cutaneous T-cell lymphoma?

JT Int J Dermatol

V 57

D 2018

P 1314-L 1319

<original_ref>[10] Holahan HM, Farah RS, Fitz S, Mott SL, Ferguson NN, McKillip J, et al. Health-related quality of life in patients with cutaneous T-cell lymphoma? Int J Dermatol. 2018;57<I>(11)</I>:1314-9.</original_ref>

</BIB>

<BIB>

11

S Engin F B.

S Keçici F A.S.

S Uzun AÖ

S Yalçın F M.

AT Psychiatric comorbidity, depression, and anxiety levels and quality of life of the patients with mycosis fungoides

JT Dermatol Ther

V 33

D 2020

P e13922

<original_ref>[11] Engin B, Keçici AS, Uzun AÖ, Yalçın M. Psychiatric comorbidity, depression, and anxiety levels and quality of life of the patients with mycosis fungoides. Dermatol Ther. 2020;33<I>(6)</I>:e13922.</original_ref>

</BIB>

<BIB>

12

S Semenov F Y.R.

S Rosenberg F A.R.

S Herbosa F C.

S Mehta-Shah F N.

S Musiek F A.C.

AT Health-related quality of life and economic implications of cutaneous T-cell lymphoma

JT Br J Dermatol

V 182

D 2020

P 190-L 196

<original_ref>[12] Semenov YR, Rosenberg AR, Herbosa C, Mehta-Shah N, Musiek AC. Health-related quality of life and economic implications of cutaneous T-cell lymphoma. Br J Dermatol. 2020;182<I>(1)</I>:190-6.</original_ref>

</BIB>

<BIB>

13

S Nguyen F M.

S LeWitt F T.

S Pang F Y.

S Bagnowski F K.

S Espinosa F M.L.

S Choi F J.<ET-AL>

AT Lifestyle, demographic and Skindex measures associated with cutaneous T-cell lymphoma:
A single institution cohort study

JT Arch Dermatol Res

V 315

D 2023

P 275-L 278

<original_ref>[13] Nguyen M, LeWitt T, Pang Y, Bagnowski K, Espinosa ML, Choi J,
et al. Lifestyle, demographic and Skindex measures associated with cutaneous T-cell
lymphoma: a single institution cohort study. Arch Dermatol Res.
2023;315<I>(2)</I>:275-8.</original_ref>

</BIB>

<BIB>

14

S Ottevanger F R.

S van Beugen F S.

S Evers F A.W.M.

S Willemze F R.

S Vermeer F M.H.

S Quint F K.D.

AT Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: A systematic
review of the literature

JT J Eur Acad Dermatol Venereol JEADV

V 35

D 2021

P 2377-L 2387

<original_ref>[14] Ottevanger R, van Beugen S, Evers AWM, Willemze R, Vermeer
MH, Quint KD. Quality of life in patients with Mycosis Fungoides and Sézary
Syndrome: a systematic review of the literature. J Eur Acad Dermatol Venereol
JEADV. 2021;35<I>(12)</I>:2377-87.</original_ref>

</BIB>

<BIB>

15

S Martinez F X.U.

S Chowdhury F A.

S Stiller F T.

S Palmer F J.

S Loscalzo F M.

S Barrios F E.<ET-AL>

AT The impact of gender, age, race/ethnicity, and stage on quality of life in a spectrum of
cutaneous lymphomas

JT Support Care Cancer Off J Multinatl Assoc Support Care Cancer

V 29

D 2021

P 6669-L 6679

<original_ref>[15] Martinez XU, Chowdhury A, Stiller T, Palmer J, Loscalzo M, Barrios E, et al. The impact of gender, age, race/ethnicity, and stage on quality of life in a spectrum of cutaneous lymphomas. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2021;29<I>(11)</I>:6669-79.</original_ref>
</BIB>

<BIB>

16

S Porkert F S.

S Lehner-Baumgartner F E.

S Valencak F J.

S Knobler F R.

S Riedl F E.

S Jonak F C.

AT Patients' Illness Perception as a Tool to Improve Individual Disease Management in Primary Cutaneous Lymphomas

JT Acta Derm Venereol.

V 98

D 2018

P 240-L 245

<original_ref>[16] Porkert S, Lehner-Baumgartner E, Valencak J, Knobler R, Riedl E, Jonak C. Patients' Illness Perception as a Tool to Improve Individual Disease Management in Primary Cutaneous Lymphomas. Acta Derm Venereol. 2018;98<I>(2)</I>:240-5.</original_ref>

</BIB>

<BIB>

17

S Navarro Matilla F B.

S Ortiz Romero F P.L.

S Pujol Vallverdú F R.M.

S Combalia Escudero F A.

S Zapata Paz F I.

S González Barca F E.<ET-AL>

AT Cost of Treating Cutaneous T-Cell Lymphoma in Spain: Analysis of MICADOS Study Data by Disease Stage [Article in English, Spanish]

JT Actas Dermosifiliogr

V 115

D 2024

P 119-L 129

<original_ref>[19] Navarro Matilla B, Ortiz Romero PL, Pujol Vallverdú RM, Combalia Escudero A, Zapata Paz I, González Barca E, et al. Cost of Treating Cutaneous T-Cell Lymphoma in Spain: Analysis of MICADOS Study Data by Disease Stage. Actas Dermosifiliogr. 2024;115<I>(2)</I>:119-29.</original_ref>

</BIB>

<BIB>

18

S Ottevanger F R.

S van Beugen F S.

S Evers F A.W.M.

S Willemze F R.

S Vermeer F M.H.

S Quint F K.D.

AT Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator

JT JAAD Int

V 9

D 2022

P 57-L 64

<original_ref>[17] Ottevanger R, van Beugen S, Evers AWM, Willemze R, Vermeer MH, Quint KD. Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator. JAAD Int. 2022;9:57-64.</original_ref>

</BIB>

<BIB>

19

S Serrano F L.

S Martinez-Escala F M.E.

S Zhou F X.A.

S Guitart F J.

AT Pruritus in Cutaneous T-Cell Lymphoma and Its Management

JT Dermatol Clin

V 36

D 2018

P 245-L 258

<original_ref>[18] Serrano L, Martinez-Escala ME, Zhou XA, Guitart J. Pruritus in Cutaneous T-Cell Lymphoma and Its Management. Dermatol Clin. 2018;36<I>(3)</I>:245-58.</original_ref>

</BIB>

</BIBL>




Figure 1 Bivariate fit of Skindex-29 values with respect to ISS. A positive association is observed between ISS and Skindex-29 values ($p < 0.001$; 95%CI, 0.908-1.922).

Table 1. Sociodemographic and Clinical Characteristics of the Sample (n = 32)

Variable	Number (%) or Mean \pm SD
Age (years)	64.19 \pm 15.28
Sex	Male: 24 (75%) Female: 8 (25%)
Type of PCL	Mycosis fungoides: 22 (68.8%), Primary cutaneous marginal zone B-cell lymphoma: 3 (9.4%) Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: 2 (6.3%) Lymphomatoid papulosis: 2 (6.3%) Large-cell PCL lymphoma: 2 (6.3%) Follicle center CTCL: 1 (3.1%)
Stage (MF, n = 22)	IA: 11 (50%) IB: 5 (22.7%) IIA: 1 (4.5%) IIIA: 2 (9.1%) IVA: 1 (4.5%) IVB: 2 (9.1%)
Stage (non-MF, n = 10)	T1aN0M0: 5 (50%) T2bN0M0: 1 (10%) T2cN0M0: 1 (10%) T3aN0M0: 2 (20%) T3bN0M0: 1 (10%)
Follow-up time (months)	MF: 46.61 \pm 37.77 Non-MF: 35.89 \pm 32.57
Number of treatments	1.97 \pm 1.4
mSWAT (MF, n = 22)	19.59 \pm 38.42
ISS	6 \pm 5.97
Skinindex-29	33.12 \pm 11.71
DLQI	4.03 \pm 4.74
HADS	Anxiety: 3.66 \pm 4.42 Depression: 2.34 \pm 3.58
WHO-5	20.31 \pm 5.46

SD, standard deviation; DLQI, Dermatology Life Quality Index; HADS, Hospital Anxiety and Depression Scale; ISS, Itch Severity Scale; CTCL: cutaneous T-cell lymphoma; PCL, primary cutaneous lymphomas; MF, mycosis fungoides; mSWAT, Modified Severity-Weighted Assessment Tool.

Table 2. Analysis of Factors Associated with Higher Scores in Skinindex-29, DLQI, HADS, and WHO-5

Variable	Skinindex-29 Mild/Moderate	Skinindex-29 Severe	p-value	DLQI No Impairment	DLQI Impairment	p-value
Age	27 (84.37%)	5 (15.6%)	0.325	29 (90.62%)	3 (9.4%)	0.039
Sex						
▪ Male	21 (65.62%)	3 (9.4%)	0.367	22 (68.75%)	2 (6.3%)	0.592
▪ Female	6 (18.75%)	2 (6.3%)		7 (21.87%)	1 (3.1%)	
Course of the disease	27 (84.37%)	5 (15.6%)	0.949	29 (90.62%)	3 (9.4%)	0.718
Number of treatments						
▪ ≤ 2	23 (71.87%)	3 (9.4%)	0.035	24 (75%)	2 (6.3%)	0.127
▪ > 2	4 (12.5%)	2 (6.3%)		5 (15.62%)	1 (3.1%)	
MF Stage						
▪ $< \text{IIB}$	14 (43.75%)	3 (9.4%)	0.675	15 (46.87%)	2 (6.3%)	0.558
▪ $\geq \text{IIB}$	4 (12.5%)	1 (3.1%)		4 (12.5%)	1 (3.1%)	
mSWAT (MF)	18 (81.81%)	4 (18.2%)	0.118	19 (86.36%)	3 (13.6%)	0.132
Pruritus						
▪ Yes	15 (46.87%)	5 (15.6%)	< 0.001	17 (53.12%)	3 (13.6%)	< 0.001

Variable	Skindex-29 Mild/Moderate	Skindex-29 Severe	p- value	DLQI No Impairment	DLQI Impairment	p- value
▪ No	12 (37.5%)	0		12 (37.5%)	0	

Scores on the Skindex-29 were classified as mild/moderate (< 44) or severe (≥ 44). For the DLQI, scores indicated no impact on quality of life (< 11) or impact (≥ 11). On the HADS, scores were categorized as unlikely case (< 10) or likely case (≥ 10) of anxiety/depression. Finally, for the WHO-5, scores suggested no impact on well-being (< 13) or impact (≥ 13).

DLQI: Dermatology Life Quality Index HADS: Hospital Anxiety and Depression Scale MF: Mycosis Fungoides; mSWAT: Modified Severity-Weighted Assessment Tool.

TRADUCCIÓN DE LA FIGURA

(corregido)

(corrected)